ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

https://oncologypro.esmo.org/Meeting-Resour...uamous-cell-carcinoma-of-the-anal-canal-SCCA

Worldwide, it is estimated that SCCA will develop in > 27,000 patients (pts). Twenty percent of pts will develop metastatic (met) disease for which there is no standard approach in the refractory setting.

Date: 29 Jun 2016
Presenter: V. Morris
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...t-on-patient-selection-for-anti-EGFR-therapy

Anti-EGFR monoclonal antibodies (MoAb) should only be considered for treatment of patients with colorectal cancer (CRC) whose tumors are wild-type (WT) for RAS genes.

Date: 29 Jun 2016
Presenter: J. Grasselli
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-colorectal-cancer-BRAFm-CRC-phase-2-results

Patients with BRAF V600-mutant colorectal cancer (BRAFm CRC) who relapse following first-line therapy have a poor prognosis, with median overall survival of just 5–6 months.

Date: 29 Jun 2016
Presenter: J. Tabernero
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-transition-in-human-colorectal-cancer-cells

Lipocalin-2 (LCN2) also known as neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa glycoprotein purified from neutrophil granules and it is observed in a wide spectrum of solid tumor cells including colorectal cancer (CRC).

Date: 29 Jun 2016
Presenter: S.L. Kim
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...KRAS-NRAS-BRAF-and-PI3K-in-Cancer-Colorectal

Long term survival was achieved in metastatic colorectal cancer. One of the cornerstones was the close the gap between the clinic and molecular biology laboratory.

Date: 29 Jun 2016
Presenter: S. Otero
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...nocarcinomas-Implications-for-Carcinogenesis

Colorectal cancer is the fourth ranking cancer worldwide and exhibits two-fold increase in industrialized countries after the age of 40s. Although there are well defined colorectal carcinomas associated...

Date: 29 Jun 2016
Presenter: D. Yildiz
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...-Gastro-intestinal-Cancer-Study-Group-GIC-SG

Several studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies.

Date: 29 Jun 2016
Presenter: J. Souglakos
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...rectal-tumor-cells-and-the-action-mechanisms

Lactobacillus helveticus SBT2171 (LH2171) is a lactic acid bacterium that inhibits excessive immune responses. We have reported that LH2171 shows inhibitory effects on proliferation of BJAB, a B lymphoma...

Date: 29 Jun 2016
Presenter: K. Baba
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ic-and-screening.-a-single-center-experience

Muir-Torre syndrome (MTS) is a rare genetic condition that predisposes individuals to skin tumors and visceral malignancies. Because of the potentially aggressive nature of internal malignancies and...

Date: 29 Jun 2016
Presenter: R. Macías
Resources: Abstract

https://oncologypro.esmo.org/Meeting-Resour...ients-with-metastatic-colorectal-cancer-mCRC

In Poland, similar to Europe, colorectal cancer is one of the most frequently diagnosed malignancy and one of the leading causes of cancer-related deaths. The median overall survival of patients with...

Date: 29 Jun 2016
Presenter: M. Krakowska
Resources: Abstract